Deal with BC Partners aims to capitalise on rising demand for off-patent versions of complex drugs

Financial Times

London

Greater London

England

United Kingdom

Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon

Nijmegen drug maker Synthon International is about to be sold to Goldman Sachs Asset Management (GSAM). This is reported by the Bloomberg news agency based on insiders. According to the sources, the deal could potentially involve around 2 billion euros.

De Nijmeegse maker van geneesmiddelen Synthon International staat op het punt te worden verkocht aan Goldman Sachs Asset Management (GSAM). Dat meldt persbureau Bloomberg op basis van ingewijden. Volgens de bronnen zou met de deal mogelijk zo’n 2 miljard euro zijn gemoeid.

Bloomberg: Synthon wisselt voor mogelijk 2 miljard van eigenaar

rd.nl

Apeldoorn

Gelderland

Netherlands

Bloomberg: Synthon may change hands for $2 billion

Ad Fontes Media

All Sides

Media Bias/Fact Check

Nikkei Inc.

Goldman's asset arm, or Gsam, has become Synthon's most likely buyer after surpassing other suitors

El brazo de activos de Goldman, o Gsam, se ha convertido en el comprador más probable de Synthon después de superar a otros pretendientes

BC Partners se acerca a la venta del fabricante holandés Synthon a Goldman Asset Arm

larepublica.co

Bogotá

Bogota

Colombia

BC Partners approaches sale of Dutch manufacturer Synthon to Goldman Asset Arm

Goldman Sachs’ asset arm is in the process of acquiring the Dutch pharmaceutical company Synthon International for 2 billion euros. Goldman Sachs Asset Management and current Synthon-owner BC Partners are in the final stages of reaching a deal and an announcement is likely in the coming days, sources involved told Bloomberg.

NL Times

Goldman Sachs set to pay €2 billion for Dutch pharma firm Synthon International

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off-patent versions […]

Sky News: The Latest News from the World

Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon – Sky News: The Latest News from the World

Goldman Sachs' alternative investment arm announced Monday its plan to acquire a majority stake in Dutch drugmaker Synthon from British investment firm BC Partners LLP, in a deal valuing Synthon at €2 billion ($2.1 billion), including debt. BC Partners will retain a minority interest in the company, though specific ownership details were not disclosed. Synthon’s Goldman Sachs to acquire a majority stake in Synthon for €2 billion

USA Herald

Goldman Unit Buys €2 Billion Drugmaker Synthon From BC Partners - USA Herald

BC Partners is close to finalising a deal to sell Dutch generic drugmaker Synthon International Holding BV to Goldman Sachs Asset Management (GSAM), according to a report by BNN Bloomberg. Sources familiar with the matter have said GSAM has emerged as the leading bidder for Synthon after outperforming other potential buyers. The deal is expected to value Synthon at approximately €2bn ($2.1bn), with BC Partners likely retaining a minority stake. …

Private Equity Wire

BC Partners agrees Synthon sale to Goldman Sachs

Goldman Sachs Alternatives' PE arm has agreed to pick up a majority stake in Synthon from BC Partners in a deal believed to value the international pharmaceutical business at about €2bn. The post Deal Roundup: BC sells Synthon stake to Goldman PE arm, valuing company at about €2bn, Stonepeak to buy Forgital from Carlyle appeared first on AltAssets Private Equity News.

Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics